摘要
目的 检测多药耐药基因MDR1mRNA在卵巢癌组织中的表达及其临床应用价值。方法 选择卵巢癌组织 30例、卵巢良性肿瘤组织 30例、正常卵巢组织 30例。采用RT PCR复合定量技术检测卵巢癌组织中耐药相关基因MDR 1mRNA的表达水平及分析其表达与临床化疗的相关性。结果 正常卵巢组织不表达MDR1基因 ;卵巢良性肿瘤组织MDR1基因表达率为10 .0 % ;卵巢癌组织表达率为 73 .3 % ,其中高表达率占 77.3 %。卵巢癌组织中MDR 1基因表达与卵巢良性肿瘤的比较 ,有非常显著性差异 (P <0 .0 1)。卵巢癌术前化疗组MDR 1基因表达率为 83 .3 % ;术前未化疗组MDR1基因表达率为 5 8.3 % ,2组比较无显著性差异 (P >0 .0 5 )。定量分析表明化疗可以诱导MDR1基因表达水平增高 ,与非化疗组比较有非常显著性差异 (P <0 .0 1)。结论 MDR1基因表达与卵巢癌有关。MDR 1表达与卵巢癌化疗与否无关 ,但化疗可诱导MDR1基因表达水平增高。因此检测MDR1基因表达水平的变化可以预测继发耐药性。在判断卵巢癌临床用药时 ,检测MDR1耐药相关基因的表达情况可得到一定的耐药信息 。
Objective To explore the gene expression of multidrug resistance gene(MDR1) in ovarian cancer tissue and its clinical significance.Methods Reverse transcription polymerase chain reaction(RT PCR) was used to determine the expression of MDR1 in ovarian carcinoma,benign tumor and normal tissue(30 cases each group).The expression rate of MDR1 and the association between this gene and chemotherapy was explored.Results The expression rate of MDR1 gene in malignant,benign tumor and normal tissue of ovary was 73.3%,10.0% and 0% respectively.In these with positive expression,77.3% of ovary cancer showed high level expression of MDR1 gene.No association was found between the expression rate of MDR1 and chemotherapy, but the level of MDR1 was higher in patients who received chemotherapy before surgery( P =0.0057).Conclusion The expression MDR1 is one of major factors associated with drug resistance in ovarian carcinoma.Chemotherapeutic agents may induce MDR1 simultaneously.
出处
《实用癌症杂志》
2001年第1期49-51,共3页
The Practical Journal of Cancer
